REG - Cizzle Biotechnology - Completion of Evaluation Programme with Bio-Techne

Cizzle Biotechnology HoldingsAnnouncement

19/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230919:nRSS8955Ma&default-theme=true

RNS Number : 8955M  Cizzle Biotechnology Holdings PLC  19 September 2023

Cizzle Biotechnology Holdings plc

 

("Cizzle" or the "Company")

 

Cizzle and Bio-Techne Announce Completion of Evaluation Programme for
Detection of CIZ1B Using ProteinSimple Branded Simple Western(TM) Platform

London/Minneapolis/September 19, 2023 -- Bio-Techne Corporation (NASDAQ: TECH)
and Cizzle Biotechnology Holdings plc, the UK-based diagnostics developer, are
pleased to announce recent progress evaluating specific monoclonal antibodies
for Cizzle's CIZ1B cancer biomarker. Cizzle has successfully completed an
evaluation programme aimed at assessing the feasibility of using the Simple
Western platform from ProteinSimple (a Bio-Techne brand) for high throughput
detection of the CIZ1B cancer biomarker which may be useful in the detection
of early-stage lung cancer.

The global lung cancer screening market is projected to grow from US$2.80
billion in 2021 to US$4.85 billion in 2028, representing a CAGR of 8.1% during
the forecast period*. Furthermore, in 2021 the United States Preventive
Services Task Force (USPSTF) updated its lung cancer screening guidelines**
for annual screening with low-dose computed tomography ("LDCT"), reducing the
lower limit of the screening age from 55 to 50 years and the minimum smoking
history from 30 to 20 pack-years. Under the new guidelines, 14.5 million
Americans may be eligible for annual screening with LDCT and other early-lung
cancer screening tests which is estimated could save an additional
10,000-20,000 lives each year.

Allan Syms, Executive Chairman of Cizzle, commented: "We are very pleased to
be working with Bio-Techne, a global leader in bioscience solutions. We
believe the Simple Western platform is an excellent fit for use in our
development of a high throughput assay for the detection of the Company's
CIZ1B biomarker. Cizzle has shown that CIZ1B is highly associated with lung
cancer at its earliest stage when surgical or other therapeutic intervention
is possible, which is key to saving lives. We look forward to building on this
important project as we push forward in bringing our novel diagnostic solution
to market."

 

Will Geist, President of Bio-Techne's Protein Sciences Segment, commented: "We
are pleased that Cizzle has chosen the Simple Western platform for the
development of its novel biomarker. The automation, sensitivity, small sample
input and quantitative nature of the Simple Western system makes it ideal for
supporting an assay of this nature. We are excited about the progress so far
and hopeful Simple Western can aid in making such a life-saving innovation
available to the patients that need it."

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 3328 5656
 John Depasquale
 George Payne

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited     +44(0) 20 3934 6630
 Tim Metcalfe

 Florence Chandler

 Bio-Techne Corporation   +1 612-656-4416

David Clair

 

About Cizzle Biotechnology

Cizzle is developing a blood test for the early detection of lung cancer. The
Company is a spin- out from the University of York, founded in 2006, around
the work of Professor Coverley and colleagues. Its proof-of-concept prototype
test is based on the ability to detect a stable plasma biomarker, a variant of
CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein
involved in DNA replication, and the targeted CIZ1B variant is highly
correlated with early-stage lung cancer. For more information, please see
https://cizzlebiotechnology.com You can also follow the Company through its
twitter account @CizzlePlc and on LinkedIn.

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company
providing innovative tools and bioactive reagents for the research and
clinical diagnostic communities.  Bio-Techne products assist scientific
investigations into biological processes and the nature and progress of
specific diseases. They aid in drug discovery efforts and provide the means
for accurate clinical tests and diagnosis. With thousands of products in its
portfolio, Bio-Techne generated approximately $1.1 billion in net sales in
fiscal 2023 and has approximately 3,200 employees worldwide.  For more
information on Bio-Techne and its brands, please visit
https://www.bio-techne.com (https://www.bio-techne.com) .

 

References

 

*Lung Cancer Screening Market Size & Share | Report, 2028
(fortunebusinessinsights.com)
(https://www.fortunebusinessinsights.com/industry-reports/lung-cancer-screening-market-101174)

** The 2021 USPSTF lung cancer screening guidelines: a new frontier - The
Lancet Respiratory Medicine
(https://www.thelancet.com/pdfs/journals/lanres/PIIS2213-2600(21)00210-1.pdf)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCLLMITMTJBMFJ